12.35
0.29 (2.40%)
| Previous Close | 12.06 |
| Open | 12.06 |
| Volume | 35,479 |
| Avg. Volume (3M) | 65,446 |
| Market Cap | 147,394,592 |
| Price / Sales | 2.50 |
| Price / Book | 2.17 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -99.17% |
| Operating Margin (TTM) | -11.05% |
| Diluted EPS (TTM) | -4.86 |
| Quarterly Revenue Growth (YOY) | 33.70% |
| Total Debt/Equity (MRQ) | 14.02% |
| Current Ratio (MRQ) | 1.81 |
| Operating Cash Flow (TTM) | -3.91 M |
| Levered Free Cash Flow (TTM) | 19.59 M |
| Return on Assets (TTM) | -6.31% |
| Return on Equity (TTM) | -304.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | LENSAR, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 3.0 |
| Average | 3.33 |
|
LENSAR Inc is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency and reproducibility by providing imaging, simplified procedure planning, efficient design and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. The consumable portion of the system consists of a disposable patient interface device, or PID, kit and a procedure license. Each procedure on each system requires the use of a PID kit. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 19.64% |
| % Held by Institutions | 44.03% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Sep 2025 | Announcement | LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 Aug 2025 | Announcement | LENSAR Reports Second Quarter 2025 Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |